Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

ve declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Financial tables follow


'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015 Stent retriever thrombectomy, an endovascular ... the brain reduced disability after stroke, according to ... President of the Society of Vascular and Interventional ... giant step forward that will change the way ... said Jovin, who is associate professor of Neurology ...
(Date:4/20/2015)... Champaign, IL (PRWEB) April 20, 2015 ... establishment of its 12th clinical research site: PMG Research ... has assumed operation of the clinical research department at ... footprint outside the Southeast to a second region within ... 150 multi-specialty physician practice enhances PMG’s access to an ...
(Date:4/20/2015)... April 20, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... the Company,s Board of Directors. Dr. Jenkins brings ... experience, having built and led teams advancing programs ... and into healthcare systems globally. ...
(Date:4/20/2015)... Lilly and Company (NYSE: LLY ) will present ... Lilly,s diverse oncology pipeline, during the American Association for ... in Philadelphia , Pa.  ... of this year,s AACR meeting and one that is ... therapies that accelerate the pace and progress of cancer ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... July 21 Innocoll Inc. today announced,that Anthony H. ... directors., Dr. Wild is a co-founder and General ... He is a member of the Boards,of Directors of ... the board of advisors of Ferrer,Freeman and Co., a ...
... diversity of research,approaches while also encouraging sharing of IP, technologies, partnerships ... ... reduced complexity, elimination of duplications and increased ... San Francisco,site to operate as an independent research and early development center ...
... The 2008 Kansas Day of,Innovation featuring the ... in Wichita, Kansas, Thursday, September 4th, 2008 at ... sponsors are focused,on providing early stage, high-growth companies ... early stage financing. "This has grown to,be a ...
Cached Biology Technology:Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors 2Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors 3Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 2Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 3Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 4Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 5Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 6Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 7Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 8Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 9Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 10Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 11Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 122008 Kansas Day of Innovation Featuring the Fifth Annual Great Plains Capital Conference Scheduled for September 2
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Over the past decades, researchers seeking to understand molecular ... of DNA microarrays to interrogate tissues specimen of patients ... once. Jointly, such gene expression status of each ... their transcripts, constitutes the gene expression profile. Since each ...
... Researchers with the Faculty of Medicine & Dentistry at ... T-cells can kill neurons. This finding is significant because ... in the medical community as a potential treatment for ... and his post-doctoral fellow, Yohannes Haile, both from the ...
... but the DNA sequence of a small plant that ... information that could influence the development of candidate biofuel ... evolution. "When you burn coal, you,re burning ... Banks, who originally proposed that the U.S. Department of ...
Cached Biology News:Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 2Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 3Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 4Discovery demonstrates potential MS therapy could kill brain cells 2Spikemoss genome offers new paths for biofuels research -- bridges plant development gap 2Spikemoss genome offers new paths for biofuels research -- bridges plant development gap 3